First, we’re hosting a networking event for healthcare investors, traders, and analysts on June 17th – details and RSVP here. It’s all about dialog, an investor’s best friend when you’ve got the right network. That’s what we want to facilitate, so come mix and mingle over drinks at Toshi’s.
Second, BioDelivery Sciences’ (BDSI) drug candidate, BUNAVAIL, just received FDA approval this Friday evening. The stock is up 11% to $10.80 in after hours trading.
The approval was no surprise to PropThink Premium readers, who’ve understood our interest since the stock traded below $5.00.
That’s not it for BDSI though. The company will report results from a critical phase 3 trial in just a month. That’s not long to get ready for a binary event that could have a profound impact on the stock. Want our take on this next inflection point? Read the report.
On Monday, we published David Phillips’ interview with IPQ Analytics CEO, Michael Liebman. Liebman is a thought leader in the field of biomedical informatics, and his firm helps industry clients improve planning and outcomes in the pharmaceutical development process. Liebman advocates for shifting R&D investment to earlier in the development process (for example, better identification of appropriate test subjects) can have major impacts on what is an incredibly expensive development process. Read, “Improving Drug Development: An Interview with IPQ Analytics CEO, Michale Liebman“.
In other news this week, Retrophin (RTRX) slumped hard after disclosing that the company’s CEO sold stock last Friday. The sale took place a day after the company announced an $80 million financing and the in-licensing of the orphan drug, Thiola (tiopronin). It’s also the same day that, during a conference call, management suggested that the Thiola acquisition was worth $10 in net present value to shareholders, and that results with another early-stage drug were “encouraging,” to be reported soon.
Retrophin has its share of skeptics, and this sale doesn’t sit well with shareholders – the stock is off almost 20% since the SEC filings hit this week. You can read the full story here.
Have a great weekend! And, join PropThink Premium for access to our proprietary research and analysis of emerging-growth healthcare companies poised for big moves – get it now.
One ore more or PropThink’s contributors are long RTRX or BDSI.
